From the Journals

Key driver of fish oil’s antidepressant effects revealed


 

No clinical implications

Weighing in on this research in a Science Media Centre statement, Kevin McConway, emeritus professor of applied statistics, The Open University, Milton Keynes, United Kingdom, said, “The point of the study was to throw some light on the mechanisms in the body by which omega-3 fatty acids might work to reduce inflammation or depression.”

“The research mostly involved cells in laboratory dishes, but it also involved treating a small sample of patients with major depression by giving them supplements of one or other of the two omega-3 acids under investigation for 12 weeks,” he noted.

“The researchers found that the patients’ average scores on a standard set of questions, used to diagnose and measure depression, improved over that 12-week period, for each of the two fatty acids.

While depression symptoms improved over 12 weeks with omega-3 fatty acid treatment, “depression symptoms change over time anyway, for many reasons,” and depressive symptoms might have improved over 12 weeks even if the patients had not been given the omega-3 acids, Dr. McConway said.

“We just can’t tell since every patient got omega-3 fatty acids. So these results can hint that omega-3 fatty acids might help in depression, but it comes nowhere near showing that this is the case with a reasonable degree of certainty,” he cautioned.

“Indeed the researchers did not carry out this part of their study to see whether the omega-3 supplements help with depression – they did it to see whether the biochemical changes that they had seen in cell cultures in the lab might also occur in human bodies,” he noted.

This research was funded in part by grants to the investigators from the U.K. Medical Research Council, the European Commission Horizon 2020, and the National Institute for Health Research (NIHR), Maudsley Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London. Dr. Borsini has received research funding from Johnson & Johnson for research on depression and inflammation. Dr. McConway is a trustee of the Science Media Centre and a member of its advisory committee.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Child suicides drive Colorado hospital to declare state of emergency
MDedge Psychiatry
Schizophrenia meds a key contributor to cognitive impairment
MDedge Psychiatry
Incorporating self-care, wellness into routines can prevent doctors’ burnout
MDedge Psychiatry
How a community-based program for SMI pivoted during the pandemic
MDedge Psychiatry
Low-dose nitrous oxide shows benefit for resistant depression
MDedge Psychiatry
Neurodegeneration complicates psychiatric care for Parkinson’s patients
MDedge Psychiatry
Cortical surface changes tied to risk for movement disorders in schizophrenia
MDedge Psychiatry
High rates of work-related trauma, PTSD in intern physicians
MDedge Psychiatry
Depression remains common among dystonia patients
MDedge Psychiatry
Risk to infant may warrant drug treatment for postpartum depression
MDedge Psychiatry